cancer inhibitors trang 14 tải miễn phí từ TAILIEUCHUNG

"cancer inhibitors" trang 14 - tải miễn phí từ Tailieuchung

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: A retrospective study

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: A retrospective study

10 52 0

Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

Thick-wall cavity predicts worse progression-free survival in lung adenocarcinoma treated with first-line EGFR-TKIs

9 75 1

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: A phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)

The search for a melanoma-tailored chemotherapy in the new era of personalized therapy: A phase II study of chemo-modulating temozolomide followed by fotemustine and a cooperative study of GOIM (Gruppo Oncologico Italia Meridionale)

8 63 1

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma

Ineffective anti PD-1 therapy after BRAF inhibitor failure in advanced melanoma

7 25 1

Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: A retrospective multi-institutional analysis

Management of medically inoperable and tyrosine kinase inhibitor-naïve early-stage lung adenocarcinoma with epidermal growth factor receptor mutations: A retrospective multi-institutional analysis

9 42 1

Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature

Chemotherapy-induced Takotsubo cardiomyopathy, a case report and review of the literature

5 22 1

The regulation of combined treatmentinduced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells

The regulation of combined treatmentinduced cell death with recombinant TRAIL and bortezomib through TRAIL signaling in TRAIL-resistant cells

12 55 1

Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: Initial experience of molecularly targeted therapy

Clinical characteristics and treatment outcomes in six cases of malignant tenosynovial giant cell tumor: Initial experience of molecularly targeted therapy

9 44 1

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?

11 47 1

The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma

The impact of FGFR1 and FRS2α expression on sorafenib treatment in metastatic renal cell carcinoma

7 32 1

HGUE-C-1 is an atypical and novel colon carcinoma cell line

HGUE-C-1 is an atypical and novel colon carcinoma cell line

16 34 1

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: Implications for sensitivity and resistance

Next generation sequencing of exceptional responders with BRAF-mutant melanoma: Implications for sensitivity and resistance

9 25 1

Complete clinical regression of a BRAF V600Emutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

Complete clinical regression of a BRAF V600Emutant pediatric glioblastoma multiforme after BRAF inhibitor therapy

5 40 1

The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells

The novel arylindolylmaleimide PDA-66 displays pronounced antiproliferative effects in acute lymphoblastic leukemia cells

9 31 1

Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

Volumetric FDG-PET predicts overall and progression- free survival after 14 days of targeted therapy in metastatic renal cell carcinoma

8 36 1

Infection risks in multiple myeloma: A systematic review and meta-analysis of randomized trials from 2015 to 2019

Infection risks in multiple myeloma: A systematic review and meta-analysis of randomized trials from 2015 to 2019

11 35 1

Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy

Digital gene expression analysis of NSCLC-patients reveals strong immune pressure, resulting in an immune escape under immunotherapy

13 45 3

Influence of cytochrome P450 and glutathione S transferase polymorphisms on response to nilotinib therapy among chronic myeloidleukemia patients from Pakistan

Influence of cytochrome P450 and glutathione S transferase polymorphisms on response to nilotinib therapy among chronic myeloidleukemia patients from Pakistan

11 9 1

Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK

Targeting autophagy increases the efficacy of proteasome inhibitor treatment in multiple myeloma by induction of apoptosis and activation of JNK

10 15 1

Green does not always mean go: A sulfated galactan from Codium isthmocladum green seaweed reduc

Green does not always mean go: A sulfated galactan from Codium isthmocladum green seaweed reduc

12 1 1

Đầu
1
2
3
4
5
6
7
8
9
10
11
12
13
[ 14 ]
Cuối

Đã phát hiện trình chặn quảng cáo AdBlock

Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.